Uroplasty To Present At The 25th Annual ROTH Growth Stock Conference - WICU12/WSEE Erie, PA News, Sports, Weather and Events

Uroplasty To Present At The 25th Annual ROTH Growth Stock Conference

  • Chris Lifestyle Category TEST

  • Chris Test 1Chris Test 1Chris Test 1Chris Test 1Chris Test 1Chris Test 1Chris Test 1Chris Test 1Chris Test 1Chris Test 1Chris Test 1
  • Monday, February 6 2012 4:05 PM EST2012-02-06 21:05:06 GMT
    Chris Test 1Chris Test 1Chris Test 1Chris Test 1Chris Test 1Chris Test 1Chris Test 1Chris Test 1Chris Test 1Chris Test 1Chris Test 1

Information contained on this page is provided by companies via press release distributed through PR Newswire, an independent third-party content provider. PR Newswire, WorldNow and this Station make no warranties or representations in connection therewith.

SOURCE Uroplasty, Inc.

MINNEAPOLIS, March 7, 2013 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, announced today that David Kaysen, President and CEO, and Darin Hammers, Vice President of US Sales, will present the Company's business strategy and financial results at the 25th Annual ROTH Growth Stock Conference at 8:30 AM PT on Monday, March 18, 2013 at The Ritz Carlton in Dana Point, CA.

Attendance at the conference is by invitation only. A live audio webcast of the presentation will be broadcast via the Internet. Those interested in listening to the webcast may access it at http://wsw.com/webcast/roth27/upi/ or through Uroplasty's website at www.uroplasty.com. An archived replay of the presentation will be available for 90 days.

About Uroplasty, Inc.

Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions.  Our primary focus is the commercialization of our Urgent® PC Neuromodulation System, the only FDA-cleared neuromodulation system that delivers percutaneous tibial nerve stimulation for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence.  We also offer Macroplastique® Implants, a urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. Please visit Uroplasty, Inc. at www.uroplasty.com.

For Further Information:

 

Uroplasty, Inc.

 

David Kaysen, President and CEO, or

 

Medi Jiwani, Vice President, CFO, Treasurer

 

952-426-6140

 

EVC Group

 

Doug Sherk/Jenifer Kirtland (Investors),

415-568-9349

 

Amy Phillips (Media), 412-327-9499

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow
3514 State St. Erie, PA 16508
Newsroom: (814)454-8812
Toll Free: 1(800)454-8812
Business offices: (814)454-5201
WICU FCC Filing
WSEE FCC Filing
Share:
Share Stories
Submit your stories to our site!
Share Photos
Share your photos in our community galleries
Mobile:
Mobile Site
Be sure to stay constantly updated with the power of WICU12 and WSEE at your fingertips
Free Android App
Free iPhone App
Free iPad App
Storm Tracker App
Droid
iPhone
iPad
All content © Copyright 2000 - 2013 WorldNow and WICU. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.
                   WICU/WSEE - 3514 State Street Erie, PA 16508 - (814) 454-5201 - info@wicu12.com